Closing the Diagnosis Gap: New Strategies to Accelerate Severe AS Detection

Research evidence excerpt

Closing the Diagnosis Gap: New Strategies to Accelerate Severe AS Detection

TD SECURITIES (USA) LLC INDUSTRY UPDATE

June 29, 2026

■Medical Supplies & Devices Closing the Diagnosis Gap: New Strategies to

■Medical Supplies & Devices:

Cardiovascular Accelerate Severe AS Detection

Joshua Jennings, M.D. THE TD COWEN INSIGHT

646 562 1333

Presentations at NY Valves 2026 demonstrated that improving severe AS diagnosis and

joshua.jennings@tdsecurities.com

referral represent a major opportunity to drive deeper TAVR penetration and expand

John Rusch, CFA utilization. The AHA Target AS Registry identified critical gaps in diagnosis and surveillance,

646 562 1324 while the UCSF DETECT-AS II trial demonstrated that automated EHR referral pathways

john.rusch@tdsecurities.com

significantly increased timely valve evaluation.

Colin Clark

646 562 1441 While transcatheter aortic valve replacement (TAVR) has transformed outcomes for patients

colin.clark@tdsecurities.com with severe aortic stenosis (AS), presentations at NY Valves 2026 highlighted that the greatest

opportunity to improve survival now lies upstream - identifying patients earlier and ensuring

they reach valve specialists before developing advanced heart failure or suffering sudden

clinical deterioration. Two complementary initiatives demonstrated how systematic quality

improvement and electronic health record (EHR)-based automation can meaningfully reduce

longstanding gaps in diagnosis, referral, and treatment. If these dynamics continue to

improve, TAVR market growth could be impacted positively.

The first presentation detailed the rapid expansion of the American Heart Association's Target

AS Registry, which is establishing national benchmarks for the quality of severe AS diagnosis

and management before valve intervention.